創傷治療用生物製剤の世界市場-2022-2029

市場力学

創傷治療用生物製剤市場の成長は、熱傷の発生率の上昇、傷害の治療における創傷治療用生物製剤の採用率の上昇、老年人口の増加、および研究開発活動によってもたらされます。

糖尿病疾患の有病率の上昇が市場成長の原動力になると予想される

糖尿病や熱傷などの疾病の発生率の上昇は、予測期間中に市場を押し上げると予想されます。2022年5月にStar Pearlsに掲載された記事によると、世界の糖尿病性足潰瘍の年間発生率は910万から2610万です。糖尿病患者の約15～25％が生涯に糖尿病性足潰瘍を発症するとされています。新たに糖尿病と診断される患者の数は年々増加しており、糖尿病性足潰瘍の発生率も上昇する傾向にあります。糖尿病性足潰瘍は、45歳以上の糖尿病患者に最も多く見られるもの、どの年齢でも発生する可能性があります。糖尿病の患者さんは、足腰の細い血管に強い動脈硬化を起こし、血管障害を引き起こしますが、これも糖尿病性足部感染症の原因の1つです。糖尿病性足部感染症では、傷口に血液が行き届かないため、治癒が遅れ、最終的には壊死や壊疽（えそ）に至ります。このような疾病の増加により、創傷治療用生物製剤の需要が世界的に高まっています。

また、市場プレイヤーは、提携や製品の上市など、さまざまな戦略を採用しています。例えば、2021年1月、インテグラライフサイエンスはACell, Inc.を買収しました。この買収により、インテグラはより包括的で複雑な創傷管理ソリューションを提供できるようになりました。

創傷治療の高コストが市場成長の妨げとなる

しかし、すべての創傷に対する医療費予測は282億米ドルから967億米ドルで、この中には感染管理のための費用も含まれており、その中でも外科的創傷と糖尿病性潰瘍は治療費が最も高額になっています。さらに、外来患者コスト（98～357億米ドル）は入院患者コスト（50～243億米ドル）よりも高く、おそらく外来での創傷治療が増加していることが原因であろう。これらの要因が市場成長を制限しています。

COVID-19の影響分析

COVID-19の登場は、世界の創傷治療用生物製剤市場にかなりの影響を与えました。主に、医療従事者は少なくとも週に1回、創傷の進行状況を評価し、デブリードメントを行ったり、CTP（皮膚代用剤）を塗ったりして、慢性創傷を治療しています。病院の外来部門の創傷クリニックは、これらの創傷を治療するための主要な治療場所でした。それでも、最初のCOVID-19の上昇時にこれらの施設の多くが閉鎖されたため、多くの慢性創傷の患者が受診しなかったり、治療が遅れたりしました。これは創傷治療市場にマイナスの影響を与えました。

一部の市場参加者は、進行中の臨床試験の遅れや中止、産業の閉鎖やコロナウイルス感染症の管理に重点を移すための政府の規制のために、新しい治療法の開発に困難に直面しました。

さらに、市場プレイヤーは、買収や新製品の発売などの市場戦略を採用することにより、事業の拡大に取り組んでいました。また、2020年11月、Stryker Corporationは、四肢と生物製剤に集中した世界医療機器企業であるWright Medical Group N.V.を買収しました。

世界の創傷ケア用生物製剤市場レポートでは、約65以上の市場データ表、65以上の図表、200ページ以上（概算）の範囲でのアクセスを提供することになります。

目次

第1章 市場調査手法とスコープ

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 熱傷の発生率の増加
    • 研究開発の増加
  • 抑制要因
    • 創傷治療用生物製剤の高コスト
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析
• プライシング分析
• アンメットニーズ分析

第6章 COVID-19分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、あるいは将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 製品タイプ別

• 生体皮膚代替物
  • 合成皮膚移植片
  • アロングラフト
  • 異種移植片
• 外用剤

第8章 創傷タイプ別

• 慢性創傷
  • 糖尿病性足潰瘍
  • 静脈性下腿潰瘍
  • 褥瘡（じょくそう
• 急性期創傷
• 外科的創傷
• 熱傷
• その他

第9章 エンドユーザー別

• 病院
• 火傷センター
• 外来手術センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 治療タイプ別ベンチマーク

第12章 企業プロファイル

• Organogenesis Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Integra Lifesciences
• Smith and Nephew
• Acell Inc.
• Osiris Therapeutics
• Avita Medical
• Solsys Medical
• Generex Biotechnology
• Mimedx
• Skye Biologics

第13章 創傷治療用生物製剤の世界市場-DataM

Market Overview

Wound care biologics market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 6.2% during the forecast period (2022-2029).

Wound care biologic therapies promote the re-establishment of the intrinsic repair mechanisms and application of these active biological agents, including plant-derived active biomolecules, which exhibit antimicrobial, antioxidant, or anti-inflammatory attributes. Biologic dressings help to prevent evaporative heat loss, water loss, protein and electrolyte loss, and contamination.

Market Dynamics

The wound care biologics market growth is driven by the rise in the incidence of burn injuries, the rising adoption of wound care biologics for treating injuries, the increase in the geriatric population, and research and development activities.

The rising prevalence of diabetes diseases is expected to drive the market growth

The rising incidence of diseases, such as diabetes and burn injuries, is expected to boost the market over the forecast period. As per the article published in Star Pearls in May 2022, the annual incidence of diabetic foot ulcers worldwide is between 9.1 to 26.1 million. Around 15 to 25% of patients with diabetes mellitus will develop a diabetic foot ulcer in their lifetime. As the number of newly diagnosed diabetics is increasing annually, the incidence of a diabetic foot ulcers is also bound to rise. Diabetic foot ulcers can arise at any age despite being most prevalent in ages 45 and over in patients with diabetes mellitus. Patients suffering from diabetes mellitus develop intense atherosclerosis of the small blood vessels in the legs and feet, directing to vascular compromise, which is another cause of diabetic foot infections. Healing is delayed, eventually leading to necrosis and gangrene because blood cannot reach the wound. The rising disease incidence leads to increasing demand for wound care biologics worldwide.

In addition, the market players are adopting different strategies, such as collaboration and product launches. For instance, in January 2021, Integra Lifesciences acquired ACell, Inc. This acquisition enabled Integra to deliver more comprehensive and complex wound management solutions.

The high cost of wound care will hamper the growth of the market

However, healthcare cost predictions for all wounds ranged from $28.2 to $96.7 billion, including costs for infection management, in which surgical wounds and diabetic ulcers were the most expensive to treat. Moreover, outpatient costs ($9.8-$35.7 billion) are higher than inpatient costs ($5.0-$24.3 billion), possibly due to increased outpatient wound treatments. These factors are limiting the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global wound care biologics market. Mainly, healthcare professionals treat chronic wounds at least once a week to assess the progress of the wound, provide debridement or apply CTPs (skin substitutes). The hospital outpatient department wound clinics had the primary care site to treat these wounds. Still, with the closing of many of these facilities during the initial COVID-19 rise, many patients with chronic wounds were not seen or delaying treatment.. This negatively affected the wound care market.

Some market players have faced difficulties developing new treatments because of the delay or cancellation of ongoing clinical trials and government restrictions to shut down the industries or to move the focus on managing the coronavirus infection.

In addition, the market players were engaged in expanding the business by adopting the market strategies such as acquisition or new product launches. Also, in November 2020, Stryker Corporation acquired Wright Medical Group N.V., a global medical devices company concentrated on extremities and biologics.

Segment Analysis

The chronic wounds segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The chronic wounds segment is expected to boost the market over the forecast period. Chronic wounds construct significant problems for patients. They are hurting and tender. Wounds often fatigue and emit odors, and involved dressings are often evident. Unprotected by an unbroken skin envelope, these wounds can be retraumatized and improvement in size. They may design an infection directed to sepsis and amputation. Patients with diabetes and obesity are at increased risk of developing chronic wounds. The vast majority of people who have a long open wound usually also have other significant health conditions. The simultaneous presence of a variety of chronic diseases is called comorbidity. Chronic wounds are usually confused by comorbidities, making it challenging to track chronic wounds as a disease.

As per the Wound Infection Clinical Practice data in 2022, the Standard clinical microbiology laboratory released outcomes that only supply information regarding a small subset of the bacterial species present, mainly in chronic wounds. If infection with fungi, mycobacteria or anaerobic bacteria is presumed, for example, following environmental contamination of a wound, this should be precisely requested or concerned with a microbiologist as these organisms need further examinations and processing. The increasing incidence and advanced diagnostics for chronic wounds drive the wound care biologic market.

Geographical Analysis

North America region holds the largest market share of the global Wound Care Biologics market

North America dominates the market for wound care biologics and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the increasing geriatric population, technological advancement, and growing research and development activities. According to the article published in Advance in Wound Care in May 2021, chronic wounds are mostly seen in the elderly. In the United States, 3% of the population aged 65 has open wounds. By 2060, the U.S. government evaluates that the elderly population will be over 77 million, signifying that chronic wounds will resume being an increasingly constant concern in these people. Around the United States, 2% of the entire population is assessed to be impacted by chronic wounds.

In addition, the market players are applying market strategies such as collaboration and new product launches. For instance, in June 2021, MIMEDX received approval from the Japanese Ministry of Health, Labour and Welfare for the commercialization of Epifix in Japan. In April 2021, Kerecis presented its Kerecis Omega3 GraftGuide, an intact fish skin that uniquely manages the challenges of burn healing.

Competitive Landscape

The wound care biologics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Organogenesis Inc., Integra Lifesciences, Smith and Nephew, Acell Inc., Osiris Therapeutics, Avita Medical, Solsys Medical, Generex Biotechnology, Mimedx, Skye Biologics among others. The major players are adopting several growth strategies, such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the wound care biologics market globally.

For instance,

• In July 2022, Biologics Company Tides Medical introduced Artacent AC, a tri-layer skin graft designed to treat complex or difficult-to-treat wounds.
• In May 2022, MIMEDX received USD 4.6 million in awards department of defense to evaluate PURION-processed Dehydrated Human Amnion Chorion Membrane (DHACM) to advance the treatment of combat casualty wounds and burns.

Zax Healthcare

Overview:

Organogenesis Inc. is a medicine company founded in 1985 and headquartered in the United States. The company offers a portfolio of acellular and bioactive biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

Product Portfolio:

PuraPly: It is an antimicrobial wound matrix is an FDA 510(k)-cleared Class II medical device used for the management of various types of wounds, including acute and chronic wound types, such as pressure ulcers, partial and full-thickness wounds, venous ulcers, chronic vascular ulcers, diabetic ulcers, tunneled/undermined wounds, draining wounds, trauma wounds, and first- and second-degree burns.

The global wound care biologics market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising incidence of burn injuries
    • 4.1.1.2. Increase research and development activities
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost of wound care biologic
  • 4.1.3. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis
• 5.4. Pricing Analysis
• 5.5. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Biological Skin Substitutes*
  • 7.2.1. Synthetic Skin Grafts
  • 7.2.2. Allografts
  • 7.2.3. Xenografts
  • 7.2.4. Introduction
  • 7.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Topical Agents

8. By Wound Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
  • 8.1.2. Market Attractiveness Index, By Wound Type
• 8.2. Chronic Wounds*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.2.3. Diabetic Foot Ulcers
  • 8.2.4. Venous Leg Ulcers
  • 8.2.5. Pressure Ulcers
• 8.3. Acute Wounds
• 8.4. Surgical Wounds
• 8.5. Burns
• 8.6. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Burn Centers
• 9.4. Ambulatory Surgical Centers
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Treatment type Benchmarking

12. Company Profiles

• 12.1. Organogenesis Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Integra Lifesciences
• 12.3. Smith and Nephew
• 12.4. Acell Inc.
• 12.5. Osiris Therapeutics
• 12.6. Avita Medical
• 12.7. Solsys Medical
• 12.8. Generex Biotechnology
• 12.9. Mimedx
• 12.10. Skye Biologics

LIST NOT EXHAUSTIVE

13. Global Wound Care Biologics market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us